Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Ani Pharmaceuticals (ANIP) EBIT (2016 - 2026)

Ani Pharmaceuticals' EBIT history spans 15 years, with the latest figure at $34.8 million for Q4 2025.

  • On a quarterly basis, EBIT rose 894.13% to $34.8 million in Q4 2025 year-over-year; TTM through Dec 2025 was $111.1 million, a 18922.77% increase, with the full-year FY2025 number at $111.1 million, up 18922.77% from a year prior.
  • EBIT hit $34.8 million in Q4 2025 for Ani Pharmaceuticals, down from $36.2 million in the prior quarter.
  • Over the last five years, EBIT for ANIP hit a ceiling of $36.2 million in Q3 2025 and a floor of -$23.7 million in Q4 2021.
  • Historically, EBIT has averaged $4.2 million across 5 years, with a median of $4.1 million in 2021.
  • Biggest five-year swings in EBIT: plummeted 7267.07% in 2021 and later soared 894.13% in 2025.
  • Tracing ANIP's EBIT over 5 years: stood at -$23.7 million in 2021, then surged by 107.67% to $1.8 million in 2022, then soared by 269.56% to $6.7 million in 2023, then tumbled by 165.09% to -$4.4 million in 2024, then soared by 894.13% to $34.8 million in 2025.
  • Business Quant data shows EBIT for ANIP at $34.8 million in Q4 2025, $36.2 million in Q3 2025, and $13.9 million in Q2 2025.